

Supplementary Materials

Table 1: pathogens isolated

<i>A. sobria</i>	1 (0.4)
<i>A. xylosoxidans</i>	1 (0.4)
<i>A. baumannii</i>	25 (10.5)
<i>C. freundii</i>	7 (3.0)
<i>E. cloacae</i>	20 (8.4)
<i>E. coli</i>	67 (28.3)
<i>K. oxytoca</i>	3 (1.27)
<i>K. pneumoniae</i>	66 (27.8)
<i>P. aeruginosa</i>	45 (19.0)
<i>P. cepacia</i>	1 (0.4)
<i>S. marcescens</i>	1 (0.4)
Total	237

Supplementary materials

Table 2: Length of stay in Hospital and ICU

Primary infection site (vs. urine)	Outcomes, Length of Stay (Beta estimate (STE); P-value)	
	Hospital LOS	ICU LOS
Abdominal Fluid	0.60 (0.27); p=0.03*	0.84 (0.48); p=0.07*
Bile	-0.10 (0.45); p=0.82	-1.58 (0.83); p=0.06
Blood	0.58 (0.26); p=0.02 *	0.98 (0.44); p= 0.03*
IV catheter	0.48 (0.82); p= 0.56	1.03 (1.41); p=0.47
Respiratory	0.96 (0.19); p < 0.001*	1.35 (0.33); p<0.001*
Other	0.74 (0.33); p=0.02*	0.61 (0.57); p= 0.28
Pathogen Isolated (vs. <i>E. coli</i>)		
<i>A. xylosoxidans</i>	1.43 (1.11); P= 0.20	1.98 (1.98); P =0.32
<i>A. baumannii</i>	0.34 (0.27); P =0.21	0.70 (0.48); P =0.15
<i>C. freundii</i>	0.60 (0.44); P =0.18	1.17 (0.79); P =0.14
<i>E. cloacae</i>	1.14 (0.31); P <0.001*	1.55 (0.55); P =0.004*
<i>K. oxytoca</i>	-20.10 (2002.2); P =0.99	-19.35 (2002.2); P =0.99
<i>K. pneumoniae</i>	0.16 (0.20); P =0.43	0.39 (0.35); P =0.27
<i>P. aeruginosa</i>	0.71 (0.22); P =0.001*	1.08 (0.39); P =0.01*
<i>P. cepacia</i>	2.11 (1.11); P =0.06	2.89 (1.98); P =0.15
<i>S. marcescens</i>	0.60 (1.12); P =0.60	0.35 (2.01); P= 0.99
Other factors		
Infection at site of transplant	-5.45 (0.16); P <0.001*	-0.93 (0.28); P <0.001*
Carbapenem sensitive	-0.17 (0.36); P =0.65	0.02 (0.63); P =0.97

Supplementary Materials

Table 3: Definitive Therapies Used in Carbapenem Resistant Infections

	Total uses (%)[†]	Monotherapy (%)[‡]	Combination therapy (%)[‡]
Aminoglycosides	18 (15.9)	3 (16.7)	15 (83.3)
Aztreonam	5 (4.4)	2 (40.0)	3 (60.0)
Cephalosporin	25 (22.1)	7 (28.0)	18 (72.0)
Cephalosporin/ β -lactamase inhibitor	9 (7.9)	5 (55.6)	4 (44.5)
Carbapenem	16 (14.2)	7 (43.8)	9 (56.3)
Fluoroquinolone	16 (14.2)	9 (56.3)	7 (43.8)
Fosfomycin	19 (16.8)	17 (89.5)	2 (10.5)
Other	13 (11.5)	2 (15.4)	11 (84.6)
Penicillin/B-lactamase inhibitor	11 (9.7)	5 (45.5)	6 (54.5)
Polymyxin	24 (21.3)	1 (4.2)	23 (95.8)

[†] Percent of total infection events (n=225)

[‡] Percent of total uses